#### ALNYLAM PHARMACEUTICALS, INC.

Form 4

October 26, 2007

### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number: 3235-0287

Check this box if no longer subject to Section 16.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Expires: January 31, 2005
Estimated average

0.5

**OMB APPROVAL** 

Form 4 or Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

burden hours per response...

Form filed by More than One Reporting

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person ** Greene Barry E			2. Issuer Name and Ticker or Trading Symbol ALNYLAM PHARMACEUTICALS, INC. [ALNY]	5. Relationship of Reporting Person(s) t Issuer  (Check all applicable)		
(Last)	(Last) (First)		3. Date of Earliest Transaction	Director 10% Owner Officer (give title Other (specify		
		( " " · ',	(Month/Day/Year)	below) below) COO		
300 THIRD STREET			10/24/2007			
(Street)			4. If Amendment, Date Original	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person		
			Filed(Month/Day/Year)			

#### CAMBRIDGE, MA 02142

(State)

(Zip)

(City)

Table I Man Daviva	tire Committee Acc	wined Disposed of	or Reneficially Owned

Person

		1 401	CI-MOH-D	ciivative	Secui	nucs Acq	uirea, Disposea o	i, or beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date 2A. Deemed (Month/Day/Year) Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)	4. Securities Acquired on(A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	
			Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)	, ,	` ,
Common Stock	10/24/2007		S(1)	700	D	\$ 30.95	19,651	D	
Common Stock	10/24/2007		S	800	D	\$ 30.96	18,851	D	
Common Stock	10/24/2007		S	400	D	\$ 30.97	18,451	D	
Common Stock	10/24/2007		S	100	D	\$ 30.98	18,351	D	
Common Stock	10/24/2007		S	300	D	\$ 31	18,051	D	

### Edgar Filing: ALNYLAM PHARMACEUTICALS, INC. - Form 4

Common Stock	10/24/2007	S	100	D	\$ 31.01	17,951	D
Common Stock	10/24/2007	S	100	D	\$ 31.02	17,851	D
Common Stock	10/24/2007	S	100	D	\$ 31.03	17,751	D
Common Stock	10/24/2007	S	1,000	D	\$ 31.04	16,751	D
Common Stock	10/24/2007	S	93	D	\$ 31.06	16,658	D
Common Stock	10/24/2007	S	300	D	\$ 31.07	16,358	D
Common Stock	10/24/2007	S	100	D	\$ 31.09	16,258	D
Common Stock	10/24/2007	S	100	D	\$ 31.1	16,158	D
Common Stock	10/24/2007	S	53	D	\$ 31.11	16,105	D
Common Stock	10/24/2007	S	100	D	\$ 31.12	16,005	D
Common Stock	10/24/2007	S	200	D	\$ 31.13	15,805	D
Common Stock	10/24/2007	S	200	D	\$ 31.15	15,605	D
Common Stock	10/24/2007	S	300	D	\$ 31.16	15,305	D
Common Stock	10/24/2007	S	947	D	\$ 31.17	14,358	D
Common Stock	10/24/2007	S	400	D	\$ 31.19	13,958	D
Common Stock	10/24/2007	S	1,400	D	\$ 31.2	12,558	D
Common Stock	10/24/2007	S	247	D	\$ 31.21	12,311	D
Common Stock	10/24/2007	S	500	D	\$ 31.22	11,811	D
Common Stock	10/24/2007	S	600	D	\$ 31.23	11,211	D
Common Stock	10/24/2007	S	100	D	\$ 31.25	11,111	D
	10/24/2007	S	400	D		10,711	D

Edgar Filing: ALNYLAM PHARMACEUTICALS, INC. - Form 4

Common Stock					\$ 31.28	
Common Stock	10/24/2007	S	300	D	\$ 31.3 10,411	D
Common Stock	10/24/2007	S	100	D	\$ 31.31 10,311	D
Common Stock	10/24/2007	S	340	D	\$ 31.34 9,971	D
Common Stock	10/24/2007	S	200	D	\$ 9,771 31.35	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	<b>:</b>	ate	Secur	ınt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
				Code V		Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

# **Reporting Owners**

Reporting Owner Name / Address	Relationships							
reporting o where remains a remainder	Director	10% Owner	Officer	Other				
Greene Barry E 300 THIRD STREET CAMBRIDGE, MA 02142			COO					

# **Signatures**

By: /s/ Patricia L. Allen, Attorney-in-Fact For: Barry E. 10/26/2007 Greene

3 Reporting Owners

### Edgar Filing: ALNYLAM PHARMACEUTICALS, INC. - Form 4

\*\*Signature of Reporting Person

Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 24, 2007.

#### **Remarks:**

This Form 4 is the second of three filed by the reporting person to report transactions occurring on October 24, 2007.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 4